恩度胸腔灌注联合顺铂化疗治疗肺癌所致的恶性胸腹水效果分析  

Effect of Endostar intrapleural perfusion combined with cisplatin chemotherapy in the treatment of malignant pleural effusion and ascites caused by lung cancer

作　　者：全颖 QUAN Ying(Panjin Central Hospital,Panjin 124010,China)

机构地区：[1]辽宁省盘锦市中心医院,124010

出　　处：《中国现代药物应用》2020年第21期123-125,共3页Chinese Journal of Modern Drug Application

摘　　要：目的探讨重组人血管内皮抑制素注射液(商品名:恩度)胸腔灌注联合顺铂化疗治疗肺癌所致的恶性胸腹水效果。方法70例肺癌所致的恶性胸腹水患者,随机分为观察组与对照组,各35例。对照组采取顺铂化疗治疗,观察组采取恩度胸腔灌注联合顺铂化疗治疗。比较两组患者临床疗效、生存质量指标、恶性胸腹水量、平均尿量、平均胸围。结果观察组临床治疗总有效率为100%(35/35),高于对照组的80%(28/35),差异具有统计学意义(P<0.05)。治疗后,观察组患者情感健康状况评分、躯体健康状况评分、社会关系评分以及卡氏健康评分分别为(84.01±5.45)、(82.21±6.01)、(87.24±3.26)、(87.45±3.01)分,均优于对照组的(75.12±4.42)、(70.56±4.21)、(72.24±3.21)、(80.12±3.01)分,差异均具有统计学意义(P<0.05)。观察组恶性胸腹水量、平均尿量、平均胸围均优于对照组,差异均具有统计学意义(P<0.05)。结论恩度胸腔灌注联合顺铂化疗治疗肺癌所致的恶性胸腹水可获得较好预后,提高患者的生存质量,减少恶性胸腹水。Objective To discuss the effect of recombinant human endostatin injection(trade name:Endostar)intrapleural perfusion combined with cisplatin chemotherapy in the treatment of malignant pleural effusion and ascites caused by lung cancer.Methods A total of 70 patients with malignant pleural effusion and ascites caused by lung cancer were randomly divided into observation group and control group,with 35 cases in each group.The control group was treated with cisplatin chemotherapy,and the observation group was treated with Endostar intrapleural perfusion combined with cisplatin chemotherapy.The clinical efficacy,quality of life indexes,malignant pleural and ascites volume,average urine volume,average chest circumference were compared between the two groups.Results The total effective rate of clinical treatment of the observation group was 100%(35/35),which was higher than 80%(28/35)of the control group,and the difference was statistically significant(P<0.05).After treatment,the emotional health status score,physical health status score,social relationship score,and Karnofsky health score of the observation group were(84.01±5.45),(82.21±6.01),(87.24±3.26)and(87.45±3.01)points,which were better than(75.12±4.42),(70.56±4.21),(72.24±3.21)and(80.12±3.01)points of the control group,and the difference was statistically significant(P<0.05).The malignant pleural and ascites volume,average urine volume,average chest circumference of the observation group were better than those of the control group,and the difference was statistically significant(P<0.05).Conclusion Endostar intrapleural perfusion combined with cisplatin chemotherapy can obtain a better prognosis in the treatment of malignant pleural effusion and ascites caused by lung cancer,and it can improve the quality of life of patients and reduce the malignant pleural effusion and ascites.

关 键 词：重组人血管内皮抑制素注射液胸腔灌注 顺铂化疗治疗 肺癌所致恶性胸腹水 效果 

分 类 号：R734.2[医药卫生—肿瘤]